论文部分内容阅读
提高肿瘤放射治疗疗效是临床医生十分重视的问题,也是肿瘤放射生物学面临的重大课题。多年来,放射生物学家在物理方面(高LET、射线、分次照射、加温治疗)和化学方面(氧效应、化疗药物合用、放射增敏剂)一直进行着不懈的努力,至今已初见成效。而其中发展最快的是放射增敏剂的研究,也较有更大的实用价值。目前,放射增敏剂已发展到第二代药物,其研究成果不仅颇受放疗医生的欢迎,还引起不少基础学科(药理、生化、细胞生物)工作者的注意。以下从本次会次第二组论文内容看到的研究动向做一简要摘述。
Raising the efficacy of tumor radiotherapy is a problem that clinicians attach great importance to, and it is also a major issue for tumor radiobiology. For many years, radiobiologists have been working tirelessly in terms of physics (high LET, radiography, fractional irradiation, warming treatment) and chemistry (oxygen effects, chemotherapeutic drug combinations, radiosensitizers). See results. The fastest growing among these is the study of radiosensitizers, which is also more practical. At present, radiosensitizers have been developed into second-generation drugs. Their research results have not only been welcomed by radiotherapy doctors, but have also attracted the attention of many basic disciplines (pharmacological, biochemical, and cell biological) workers. The following is a brief summary of research trends seen from the content of the second group of papers at this meeting.